Epocrates (Nasdaq: EPOC) is expected to report Q3 earnings on Oct. 30. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Epocrates's revenues will drop -4.0% and EPS will wane -100.0%.

The average estimate for revenue is $25.5 million. On the bottom line, the average EPS estimate is $0.00.

Revenue details
 Last quarter, Epocrates reported revenue of $26.8 million. GAAP reported sales were 3.7% lower than the prior-year quarter's $27.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.03. GAAP EPS were -$0.02 for Q2 against $0.14 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 59.2%, 570 basis points worse than the prior-year quarter. Operating margin was -5.3%, 760 basis points worse than the prior-year quarter. Net margin was -1.5%, 1,370 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $109.9 million. The average EPS estimate is $0.17.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 33 members out of 36 rating the stock outperform, and three members rating it underperform. Among eight CAPS All-Star picks (recommendations by the highest-ranked CAPS members), eight give Epocrates a green thumbs-up, and give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Epocrates is outperform, with an average price target of $10.00.